VectorY

Invest-NL is investing €7 million in Amsterdam-based VectorY Therapeutics. Together with existing and new investors, including Angelini Ventures and the European Investment Bank, Invest-NL is enabling a funding round of €74.5 million. The funding supports clinical research into a potential treatment for ALS and the further development of technology for the targeted delivery of antibodies in other neurological disorders.